Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy.
Camacho
Ivan D
ID
Valencia
Isabel
I
Rivas
Maria P
MP
Burdick
Anne E
AE
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D015439:Leprosy, Borderline / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab